ZNTL (STOCKS)
Zentalis Pharmaceuticals, Inc. Common Stock
$3.640000
-0.650000 (-15.15%)
Prev close: $4.290000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Julia Marie Eastland
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $297.44M
- Employees
- 166
- P/E (TTM)
- -2.19
- P/B (TTM)
- 2.14
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $153.37M |
| Research and Development | $116.32M |
| Other Operating Expenses | $37.06M |
| Operating Income/Loss | -$153.37M |
| Income/Loss From Continuing Operations After Tax | -$139.55M |
| Income/Loss From Continuing Operations Before Tax | -$138.85M |
| Income Tax Expense/Benefit | $700.00K |
| Net Income/Loss | -$139.55M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$139.55M |
| Net Income/Loss Available To Common Stockholders, Basic | -$139.55M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.96 |
| Diluted Earnings Per Share | -$1.96 |
| Basic Average Shares | 142,868,000 |
| Diluted Average Shares | 142,868,000 |
| Assets | $215.33M |
| Current Assets | $181.28M |
| Noncurrent Assets | $34.05M |
| Fixed Assets | $2.50M |
| Other Non-current Assets | $31.55M |
| Liabilities | $71.68M |
| Current Liabilities | $37.63M |
| Accounts Payable | $8.14M |
| Wages | $6.42M |
| Other Current Liabilities | $23.06M |
| Noncurrent Liabilities | $34.06M |
| Equity | $143.65M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $143.65M |
| Liabilities And Equity | $215.33M |
| Net Cash Flow From Operating Activities | -$128.10M |
| Net Cash Flow From Operating Activities, Continuing | -$128.10M |
| Net Cash Flow From Investing Activities | $120.81M |
| Net Cash Flow From Investing Activities, Continuing | $120.81M |
| Net Cash Flow From Financing Activities | -$5.53M |
| Net Cash Flow From Financing Activities, Continuing | -$5.53M |
| Net Cash Flow | -$12.82M |
| Net Cash Flow, Continuing | -$12.82M |
| Comprehensive Income/Loss | -$139.68M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$139.68M |
| Other Comprehensive Income/Loss | -$77.78M |
| Other Comprehensive Income/Loss Attributable To Parent | -$137.00K |